Impax Labs Inc (IPXL) 30.62 $IPXL
Impax to Report Second Quarter 2016 Results on August 9, 2016
PR Newswire - Thu Jul 07, 7:05AM CDT
Impax Laboratories, Inc. (NASDAQ: IPXL) announced today that the Company will release its second quarter 2016 financial results on Tuesday, August 9, 2016, prior to the open of the U.S. financial markets. The Company will host a conference call and live webcast with the investment community at 8:30 a.m., Eastern Time on August 9, 2016.
IPXL: 30.62 (+1.27)
Impax (IPXL) Stock Declines on Deal to Buy Generic Products
Arpita Dutt - Zacks Investment Research - Wed Jun 22, 9:20AM CDT
Impax's (IPXL) stock declined 11.5% following the company's announcement regarding the acquisition of generic products.
IPXL: 30.62 (+1.27), AGN: 238.28 (-2.31), TEVA: 50.93 (+0.04), AMPH: 16.94 (+0.14)
Upgrade Alert for Impax Laboratories (IPXL)
Comtex SmarTrend(R) - Wed Jun 22, 3:33AM CDT
Impax Laboratories (NASDAQ:IPXL) was upgraded from Underperform to Neutral at BofA/Merrill today. The stock closed yesterday at $28.31 on volume of 3.0 million shares, above average daily volume of 539,000. Potential upside of 70.4% exists for Impax Laboratories, based on a current level of $28.31 and analysts' average consensus price target of $48.25. Impax Laboratories shares should first meet resistance at the 50-day moving average (MA) of $33.81 and find additional resistance at the 200-day MA of $38.86.
IPXL: 30.62 (+1.27)
United and American Science jump, Werner and Impax slump
AP - Tue Jun 21, 3:43PM CDT
NEW YORK (AP) — Stocks that moved substantially or traded heavily on Tuesday:
AGN: 238.28 (-2.31), IPXL: 30.62 (+1.27), CP.TO: 174.45 (+0.55), WERN: 23.81 (-0.01), CP: 133.01 (-0.34), ASEI: 37.24 (-0.13), IMPV: 48.14 (+3.38), UAL: 42.41 (+0.93)
Look for Shares of Impax Laboratories to Potentially Rebound after Yesterday's 11.26% Sell Off
Comtex SmarTrend(R) - Tue Jun 21, 3:09PM CDT
Impax Laboratories (NASDAQ:IPXL) traded in a range yesterday that spanned from a low of $28.11 to a high of $30.00. Yesterday, the shares fell 11.3%, which took the trading range below the 3-day low of $31.31 on volume of 1.5 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
IPXL: 30.62 (+1.27)
Impax Signs Definitive Agreements to Acquire Generic Products
PR Newswire - Tue Jun 21, 6:00AM CDT
Impax Laboratories, Inc. (NASDAQ: IPXL), a specialty pharmaceutical company, today announced that it has signed definitive agreements with Teva Pharmaceutical Industries Ltd. ("Teva"
and affiliates of Allergan plc ("Allergan" for the acquisition of a broad portfolio of generic products across solid oral, inhalable, injectable and topical dosage forms and the return to Impax of its rights to its pending abbreviated new drug application ("ANDA" for the generic equivalent to Concerta® (methylphenidate hydrochloride) (the "Transaction" for an aggregate purchase price of $586 million.
IPXL: 30.62 (+1.27), AGN: 238.28 (-2.31)
Impax to Present at the Goldman Sachs 37th Annual Global Healthcare Conference
PR Newswire - Thu Jun 02, 3:10PM CDT
Impax Laboratories, Inc. (NASDAQ: IPXL) today announced that the Company will present at the Goldman Sachs 37th Annual Global Healthcare Conference on Wednesday, June 8, 2016 at 2:40 p.m. Pacific Time. The conference will be held in Rancho Palos Verdes, CA.
IPXL: 30.62 (+1.27)
Impax Labs reports 1Q loss
Automated Insights - Tue May 10, 5:48AM CDT
HAYWARD, Calif. (AP) _ Impax Laboratories Inc. (IPXL) on Tuesday reported a loss of $10.4 million in its first quarter.
IPXL: 30.62 (+1.27)
Impax Reports First Quarter 2016 Financial Results
PR Newswire - Tue May 10, 5:40AM CDT
Impax Laboratories, Inc. (NASDAQ: IPXL), a specialty pharmaceutical company, today reported first quarter 2016 financial results for the quarter ended March 31, 2016.
IPXL: 30.62 (+1.27)
Is a Surprise Coming for Impax Laboratories (IPXL) This Earnings Season?
Zacks Equity Research - Zacks Investment Research - Mon May 09, 7:48AM CDT
A positive Earnings ESP coupled with impressive Zacks Rank has made Impax Laboratories (IPXL) an interesting choice for the investors.
IPXL: 30.62 (+1.27)
Jazz (JAZZ) Q1 Earnings: A Beat in the Cards for the Stock?
Zacks Equity Research - Zacks Investment Research - Fri May 06, 4:13PM CDT
Jazz Pharmaceuticals (JAZZ), which is set to report first-quarter 2016 results on May 10, delivered a positive earnings surprise of 36.75% last quarter.
IPXL: 30.62 (+1.27), CLSN: 1.30 (unch), JAZZ: 140.16 (+0.28)
What's in the Cards for Catalyst (CPRX) in Q1 Earnings?
Zacks Equity Research - Zacks Investment Research - Fri May 06, 11:18AM CDT
Catalyst Pharmaceuticals, Inc. (CPRX) is scheduled to report first-quarter 2016 results on May 10.
IPXL: 30.62 (+1.27), CPRX: 0.80 (unch), JAZZ: 140.16 (+0.28), XON: 26.23 (-0.49)
Intrexon (XON): Stock Likely to Beat Estimates in Q1 Earnings
Zacks Equity Research - Zacks Investment Research - Thu May 05, 5:49PM CDT
Intrexon (XON), which is set to report first-quarter 2016 results on May 10, delivered a positive surprise of 5.56% last quarter.
IPXL: 30.62 (+1.27), FCSC: 1.18 (-0.02), JAZZ: 140.16 (+0.28), XON: 26.23 (-0.49)
Will BioDelivery (BDSI) Disappoint Estimates in Q1 Earnings?
Zacks Equity Research - Zacks Investment Research - Thu May 05, 5:47PM CDT
BioDelivery Sciences (BDSI), which is set to report first-quarter 2016 results on May 10, reported a negative earnings surprise of 63.64% last quarter.
IPXL: 30.62 (+1.27), BDSI: 2.51 (-0.07), ENDP: 17.16 (-0.26), JAZZ: 140.16 (+0.28)
What's in the Cards for Synta (SNTA) This Earnings Season?
Zacks Equity Research - Zacks Investment Research - Thu May 05, 4:58AM CDT
Synta Pharmaceuticals (SNTA), which is expected to report first-quarter 2016 results on May 5, had posted a positive surprise of 21.52% last quarter.
IPXL: 30.62 (+1.27), SNTA: 0.26 (-0.02), JAZZ: 140.16 (+0.28), BIND: 0.53 (-0.03)
What Awaits Puma Biotechnology (PBYI) in Q1 Earnings?
Zacks Equity Research - Zacks Investment Research - Wed May 04, 2:58PM CDT
Puma Biotechnology (PBYI) is expected to report first-quarter 2016 results on May 9.
IPXL: 30.62 (+1.27), JAZZ: 140.16 (+0.28), PBYI: 34.49 (-0.39)
Inovio (INO): What's in Store for the Stock in Q1 Earnings?
Zacks Equity Research - Zacks Investment Research - Wed May 04, 10:03AM CDT
Inovio (INO) is scheduled to report first-quarter 2015 results on May 9, before the opening bell.
IPXL: 30.62 (+1.27), INO: 9.12 (+0.01), JAZZ: 140.16 (+0.28), AZN: 29.97 (-0.14)
What's in Store for Horizon (HZNP) This Earnings Season?
Zacks Equity Research - Zacks Investment Research - Wed May 04, 9:40AM CDT
Horizon Pharma (HZNP), which is set to report first-quarter 2016 results on May 9, recorded a negative earnings surprise of 20% last quarter.
IPXL: 30.62 (+1.27), JAZZ: 140.16 (+0.28), HZNP: 19.12 (+0.41), BIND: 0.53 (-0.03)
Impax to Present at the Bank of America Merrill Lynch 2016 Health Care Conference
PR Newswire - Wed May 04, 7:15AM CDT
Impax Laboratories, Inc. (NASDAQ: IPXL) today announced that the Company will present at the Bank of America Merrill Lynch 2016 Health Care Conference on Tuesday, May 10, 2016 at 9:20 a.m. Pacific Time. The conference will be held in Las Vegas, NV.
IPXL: 30.62 (+1.27)
Conatus (CNAT): Can the Stock Surprise in Q1 Earnings?
Zacks Equity Research - Zacks Investment Research - Tue May 03, 5:57PM CDT
Conatus (CNAT) is scheduled to report first-quarter 2016 results on May 5, before market opens.
ZTS: 48.29 (-0.21), IPXL: 30.62 (+1.27), CNAT: 2.21 (+0.02), JAZZ: 140.16 (+0.28)
Impax to Report Second Quarter 2016 Results on August 9, 2016
PR Newswire - Thu Jul 07, 7:05AM CDT
Impax Laboratories, Inc. (NASDAQ: IPXL) announced today that the Company will release its second quarter 2016 financial results on Tuesday, August 9, 2016, prior to the open of the U.S. financial markets. The Company will host a conference call and live webcast with the investment community at 8:30 a.m., Eastern Time on August 9, 2016.
IPXL: 30.62 (+1.27)
Impax (IPXL) Stock Declines on Deal to Buy Generic Products
Arpita Dutt - Zacks Investment Research - Wed Jun 22, 9:20AM CDT
Impax's (IPXL) stock declined 11.5% following the company's announcement regarding the acquisition of generic products.
IPXL: 30.62 (+1.27), AGN: 238.28 (-2.31), TEVA: 50.93 (+0.04), AMPH: 16.94 (+0.14)
Upgrade Alert for Impax Laboratories (IPXL)
Comtex SmarTrend(R) - Wed Jun 22, 3:33AM CDT
Impax Laboratories (NASDAQ:IPXL) was upgraded from Underperform to Neutral at BofA/Merrill today. The stock closed yesterday at $28.31 on volume of 3.0 million shares, above average daily volume of 539,000. Potential upside of 70.4% exists for Impax Laboratories, based on a current level of $28.31 and analysts' average consensus price target of $48.25. Impax Laboratories shares should first meet resistance at the 50-day moving average (MA) of $33.81 and find additional resistance at the 200-day MA of $38.86.
IPXL: 30.62 (+1.27)
United and American Science jump, Werner and Impax slump
AP - Tue Jun 21, 3:43PM CDT
NEW YORK (AP) — Stocks that moved substantially or traded heavily on Tuesday:
AGN: 238.28 (-2.31), IPXL: 30.62 (+1.27), CP.TO: 174.45 (+0.55), WERN: 23.81 (-0.01), CP: 133.01 (-0.34), ASEI: 37.24 (-0.13), IMPV: 48.14 (+3.38), UAL: 42.41 (+0.93)
Look for Shares of Impax Laboratories to Potentially Rebound after Yesterday's 11.26% Sell Off
Comtex SmarTrend(R) - Tue Jun 21, 3:09PM CDT
Impax Laboratories (NASDAQ:IPXL) traded in a range yesterday that spanned from a low of $28.11 to a high of $30.00. Yesterday, the shares fell 11.3%, which took the trading range below the 3-day low of $31.31 on volume of 1.5 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
IPXL: 30.62 (+1.27)
Impax Signs Definitive Agreements to Acquire Generic Products
PR Newswire - Tue Jun 21, 6:00AM CDT
Impax Laboratories, Inc. (NASDAQ: IPXL), a specialty pharmaceutical company, today announced that it has signed definitive agreements with Teva Pharmaceutical Industries Ltd. ("Teva"
and affiliates of Allergan plc ("Allergan" for the acquisition of a broad portfolio of generic products across solid oral, inhalable, injectable and topical dosage forms and the return to Impax of its rights to its pending abbreviated new drug application ("ANDA" for the generic equivalent to Concerta® (methylphenidate hydrochloride) (the "Transaction" for an aggregate purchase price of $586 million. IPXL: 30.62 (+1.27), AGN: 238.28 (-2.31)
Impax to Present at the Goldman Sachs 37th Annual Global Healthcare Conference
PR Newswire - Thu Jun 02, 3:10PM CDT
Impax Laboratories, Inc. (NASDAQ: IPXL) today announced that the Company will present at the Goldman Sachs 37th Annual Global Healthcare Conference on Wednesday, June 8, 2016 at 2:40 p.m. Pacific Time. The conference will be held in Rancho Palos Verdes, CA.
IPXL: 30.62 (+1.27)
Impax Labs reports 1Q loss
Automated Insights - Tue May 10, 5:48AM CDT
HAYWARD, Calif. (AP) _ Impax Laboratories Inc. (IPXL) on Tuesday reported a loss of $10.4 million in its first quarter.
IPXL: 30.62 (+1.27)
Impax Reports First Quarter 2016 Financial Results
PR Newswire - Tue May 10, 5:40AM CDT
Impax Laboratories, Inc. (NASDAQ: IPXL), a specialty pharmaceutical company, today reported first quarter 2016 financial results for the quarter ended March 31, 2016.
IPXL: 30.62 (+1.27)
Is a Surprise Coming for Impax Laboratories (IPXL) This Earnings Season?
Zacks Equity Research - Zacks Investment Research - Mon May 09, 7:48AM CDT
A positive Earnings ESP coupled with impressive Zacks Rank has made Impax Laboratories (IPXL) an interesting choice for the investors.
IPXL: 30.62 (+1.27)
Jazz (JAZZ) Q1 Earnings: A Beat in the Cards for the Stock?
Zacks Equity Research - Zacks Investment Research - Fri May 06, 4:13PM CDT
Jazz Pharmaceuticals (JAZZ), which is set to report first-quarter 2016 results on May 10, delivered a positive earnings surprise of 36.75% last quarter.
IPXL: 30.62 (+1.27), CLSN: 1.30 (unch), JAZZ: 140.16 (+0.28)
What's in the Cards for Catalyst (CPRX) in Q1 Earnings?
Zacks Equity Research - Zacks Investment Research - Fri May 06, 11:18AM CDT
Catalyst Pharmaceuticals, Inc. (CPRX) is scheduled to report first-quarter 2016 results on May 10.
IPXL: 30.62 (+1.27), CPRX: 0.80 (unch), JAZZ: 140.16 (+0.28), XON: 26.23 (-0.49)
Intrexon (XON): Stock Likely to Beat Estimates in Q1 Earnings
Zacks Equity Research - Zacks Investment Research - Thu May 05, 5:49PM CDT
Intrexon (XON), which is set to report first-quarter 2016 results on May 10, delivered a positive surprise of 5.56% last quarter.
IPXL: 30.62 (+1.27), FCSC: 1.18 (-0.02), JAZZ: 140.16 (+0.28), XON: 26.23 (-0.49)
Will BioDelivery (BDSI) Disappoint Estimates in Q1 Earnings?
Zacks Equity Research - Zacks Investment Research - Thu May 05, 5:47PM CDT
BioDelivery Sciences (BDSI), which is set to report first-quarter 2016 results on May 10, reported a negative earnings surprise of 63.64% last quarter.
IPXL: 30.62 (+1.27), BDSI: 2.51 (-0.07), ENDP: 17.16 (-0.26), JAZZ: 140.16 (+0.28)
What's in the Cards for Synta (SNTA) This Earnings Season?
Zacks Equity Research - Zacks Investment Research - Thu May 05, 4:58AM CDT
Synta Pharmaceuticals (SNTA), which is expected to report first-quarter 2016 results on May 5, had posted a positive surprise of 21.52% last quarter.
IPXL: 30.62 (+1.27), SNTA: 0.26 (-0.02), JAZZ: 140.16 (+0.28), BIND: 0.53 (-0.03)
What Awaits Puma Biotechnology (PBYI) in Q1 Earnings?
Zacks Equity Research - Zacks Investment Research - Wed May 04, 2:58PM CDT
Puma Biotechnology (PBYI) is expected to report first-quarter 2016 results on May 9.
IPXL: 30.62 (+1.27), JAZZ: 140.16 (+0.28), PBYI: 34.49 (-0.39)
Inovio (INO): What's in Store for the Stock in Q1 Earnings?
Zacks Equity Research - Zacks Investment Research - Wed May 04, 10:03AM CDT
Inovio (INO) is scheduled to report first-quarter 2015 results on May 9, before the opening bell.
IPXL: 30.62 (+1.27), INO: 9.12 (+0.01), JAZZ: 140.16 (+0.28), AZN: 29.97 (-0.14)
What's in Store for Horizon (HZNP) This Earnings Season?
Zacks Equity Research - Zacks Investment Research - Wed May 04, 9:40AM CDT
Horizon Pharma (HZNP), which is set to report first-quarter 2016 results on May 9, recorded a negative earnings surprise of 20% last quarter.
IPXL: 30.62 (+1.27), JAZZ: 140.16 (+0.28), HZNP: 19.12 (+0.41), BIND: 0.53 (-0.03)
Impax to Present at the Bank of America Merrill Lynch 2016 Health Care Conference
PR Newswire - Wed May 04, 7:15AM CDT
Impax Laboratories, Inc. (NASDAQ: IPXL) today announced that the Company will present at the Bank of America Merrill Lynch 2016 Health Care Conference on Tuesday, May 10, 2016 at 9:20 a.m. Pacific Time. The conference will be held in Las Vegas, NV.
IPXL: 30.62 (+1.27)
Conatus (CNAT): Can the Stock Surprise in Q1 Earnings?
Zacks Equity Research - Zacks Investment Research - Tue May 03, 5:57PM CDT
Conatus (CNAT) is scheduled to report first-quarter 2016 results on May 5, before market opens.
ZTS: 48.29 (-0.21), IPXL: 30.62 (+1.27), CNAT: 2.21 (+0.02), JAZZ: 140.16 (+0.28)
